Published in Ann Rheum Dis on February 21, 2008
Determining the Lowest Optimally Effective Methotrexate Dose for Individual RA Patients Using Their Dose Response Relation in a Tight Control Treatment Approach. PLoS One (2016) 1.37
Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs. Arthritis Res Ther (2012) 0.95
Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J (2012) 0.92
When should we use parenteral methotrexate? Clin Rheumatol (2010) 0.91
Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand? Int J Rheumatol (2012) 0.90
Early remission is associated with improved survival in patients with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis (2013) 0.88
Methotrexate attenuates the Th17/IL-17 levels in peripheral blood mononuclear cells from healthy individuals and RA patients. Rheumatol Int (2011) 0.86
Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year. Arthritis Care Res (Hoboken) (2012) 0.84
Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? BMC Med (2013) 0.82
Rheumatoid factor positivity is associated with increased joint destruction and upregulation of matrix metalloproteinase 9 and cathepsin k gene expression in the peripheral blood in rheumatoid arthritic patients treated with methotrexate. Int J Rheumatol (2013) 0.79
Predicting and verifying outcome of Tripterygium wilfordii Hook F. based therapy in rheumatoid arthritis: from open to double-blinded randomized trial. Sci Rep (2015) 0.77
Low serum levels of myeloid progenitor inhibitory factor-1 predict good response to methotrexate in rheumatoid arthritis. ISRN Inflamm (2013) 0.75
The contribution of four immunogenetic markers for predicting persistent activity in patients with recent-onset rheumatoid arthritis or undifferentiated arthritis. ISRN Rheumatol (2011) 0.75
[Personalized medicine in the choice of conventional immunosuppressants and disease modifying antirheumatic drugs]. Z Rheumatol (2013) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med (2000) 10.21
Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum (2002) 7.95
Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol (1986) 5.82
The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol (1994) 3.82
Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2007) 3.66
Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med (1999) 3.10
Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum (2000) 2.92
A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum (2007) 2.36
The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) (2002) 1.69
A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis Rheum (2000) 1.61
Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis (2003) 1.60
Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol (2002) 1.40
The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford) (2005) 1.29
Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum (2006) 1.27
Scores for functional disability in patients with rheumatoid arthritis are correlated at higher levels with pain scores than with radiographic scores. Arthritis Rheum (2000) 1.25
The Dunlop-Dottridge Lecture: prognosis in inflammatory arthritis: the value of HLA genotyping and the oncological analogy. J Rheumatol (1997) 1.23
HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments. Ann Rheum Dis (1998) 1.14
Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol (2002) 1.07
Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum (2000) 6.88
Flocculation tests with electrophoretically separated serum proteins. Biochem J (1947) 5.88
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis (2009) 5.82
Outcome of low back pain in general practice: a prospective study. BMJ (1998) 5.27
Features of somatization predict the onset of chronic widespread pain: results of a large population-based study. Arthritis Rheum (2001) 4.85
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2006) 4.20
The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) (2002) 3.87
The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol (1994) 3.82
Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) (2006) 3.73
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2007) 3.34
Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol (1993) 3.33
Calcium and Phosphorus Deficiencies in Poor Dietary. Br Med J (1938) 3.33
The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res (1996) 3.25
Estimating the prevalence of low back pain in the general population. Evidence from the South Manchester Back Pain Survey. Spine (Phila Pa 1976) (1995) 3.18
Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2002) 3.16
Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum (2003) 2.97
Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum (1997) 2.90
A comparison of the performance of different methods of disease classification for rheumatoid arthritis. Results of an analysis from a nationwide twin study. J Rheumatol (1994) 2.87
Widespread body pain and mortality: prospective population based study. BMJ (2001) 2.85
A disease severity scale for systemic sclerosis: development and testing. J Rheumatol (1999) 2.85
Sjögren's syndrome: a community-based study of prevalence and impact. Br J Rheumatol (1998) 2.67
The role of psychosocial factors in predicting the onset of chronic widespread pain: results from a prospective population-based study. Rheumatology (Oxford) (2006) 2.66
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis (2009) 2.65
Predicting who develops chronic low back pain in primary care: a prospective study. BMJ (1999) 2.62
Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol (1993) 2.56
Role of mechanical and psychosocial factors in the onset of forearm pain: prospective population based study. BMJ (2000) 2.56
Validity of self-report of fractures: results from a prospective study in men and women across Europe. EPOS Study Group. European Prospective Osteoporosis Study Group. Osteoporos Int (2000) 2.52
Age-sex registers as a screening tool for general practice: size of the wrong address problem. Br Med J (Clin Res Ed) (1984) 2.51
Estimating the prevalence of delayed median nerve conduction in the general population. Br J Rheumatol (1998) 2.50
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis (2001) 2.49
Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum (2007) 2.46
Occupational risk factors for shoulder pain: a systematic review. Occup Environ Med (2000) 2.40
Susceptibility to melanoma: influence of skin type and polymorphism in the melanocyte stimulating hormone receptor gene. J Invest Dermatol (1998) 2.37
Development and validation of a questionnaire to assess disabling foot pain. Pain (2000) 2.34
Prevalence of shoulder pain in the community: the influence of case definition. Ann Rheum Dis (1997) 2.28
The prevalence and associated features of chronic widespread pain in the community using the 'Manchester' definition of chronic widespread pain. Rheumatology (Oxford) (1999) 2.21
Influence of previous pain experience on the episode incidence of low back pain: results from the South Manchester Back Pain Study. Pain (1996) 2.17
Classification criteria for rheumatoid arthritis--time to abandon rheumatoid factor? Rheumatology (Oxford) (2007) 2.15
The Arthritis and Rheumatism Council's National Repository of Family Material: pedigrees from the first 100 rheumatoid arthritis families containing affected sibling pairs. Br J Rheumatol (1994) 2.14
A family history of fracture and fracture risk: a meta-analysis. Bone (2004) 2.13
Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis (2005) 2.11
Musculoskeletal pain is associated with a long-term increased risk of cancer and cardiovascular-related mortality. Rheumatology (Oxford) (2009) 2.09
Differences in the characteristics of responders and non-responders in a prevalence survey of vertebral osteoporosis. European Vertebral Osteoporosis Study Group. Osteoporos Int (1995) 2.09
Risk factors for neck pain: a longitudinal study in the general population. Pain (2001) 2.06
Psychosocial factors in the workplace--do they predict new episodes of low back pain? Evidence from the South Manchester Back Pain Study. Spine (Phila Pa 1976) (1997) 2.01
Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis (2008) 2.01
Is musculoskeletal pain more common now than 40 years ago?: Two population-based cross-sectional studies. Rheumatology (Oxford) (2005) 1.99
Psychologic distress and low back pain. Evidence from a prospective study in the general population. Spine (Phila Pa 1976) (1995) 1.98
Relation of risk of systemic lupus erythematosus to west African admixture in a Caribbean population. Hum Genet (2003) 1.97
Radiographic osteoarthritis of the knee classified by the Ahlbäck and Kellgren & Lawrence systems for the tibiofemoral joint in people aged 35-54 years with chronic knee pain. Ann Rheum Dis (1997) 1.95
Mannose-binding protein gene polymorphism in systemic lupus erythematosus. Arthritis Rheum (1995) 1.94
Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum (1999) 1.94
Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford) (2008) 1.91
Chronic widespread pain in the community: the influence of psychological symptoms and mental disorder on healthcare seeking behavior. J Rheumatol (1999) 1.90
Regional differences in survival from cancer. Community Med (1981) 1.85
Widespread pain: is an improved classification possible? J Rheumatol (1996) 1.83
Incidence of distal forearm fracture in British men and women. Osteoporos Int (2001) 1.79
Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (1999) 1.79
Clinical signs of early osteoarthritis: reproducibility and relation to x ray changes in 541 women in the general population. Ann Rheum Dis (1991) 1.79
Estimating the incidence of rheumatoid arthritis: trying to hit a moving target? Arthritis Rheum (1999) 1.78
The influence of diet upon ketonaemia in pregnant ewes. J Physiol (1938) 1.77
Mortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (1998) 1.76
The influence of work related psychosocial factors and psychological distress on regional musculoskeletal pain: a study of newly employed workers. J Rheumatol (2001) 1.72
Time to first occurrence of erosions in inflammatory polyarthritis: results from a prospective community-based study. Arthritis Rheum (2001) 1.71
The association of cigarette smoking with disease outcome in patients with early inflammatory polyarthritis. Arthritis Rheum (2001) 1.71
The grading of hallux valgus. The Manchester Scale. J Am Podiatr Med Assoc (2001) 1.70
Health-related quality of life and radiographic vertebral fracture. Osteoporos Int (2003) 1.70
Natural remission in inflammatory polyarthritis: issues of definition and prediction. Br J Rheumatol (1996) 1.67
Behçet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) (1999) 1.66
The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. American Rheumatism Association. J Rheumatol (1998) 1.63
Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. Ann Rheum Dis (2009) 1.63
The pharmacogenetics of methotrexate. Rheumatology (Oxford) (2007) 1.63
The pill, parity, and rheumatoid arthritis. Arthritis Rheum (1990) 1.62
Population genetics of rheumatoid arthritis. Rheum Dis Clin North Am (1992) 1.61
Low back pain in schoolchildren: the role of mechanical and psychosocial factors. Arch Dis Child (2003) 1.61
The distribution, determinants, and clinical correlates of vertebral osteophytosis: a population based survey. J Rheumatol (1999) 1.60
The Norfolk Arthritis Register (NOAR). Clin Exp Rheumatol (2004) 1.60
Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response. Arthritis Rheum (1987) 1.60
Polymyalgia rheumatica can be distinguished from late onset rheumatoid arthritis at baseline: results of a 5-yr prospective study. Rheumatology (Oxford) (2008) 1.60
Investigating the HLA component in rheumatoid arthritis: an additive (dominant) mode of inheritance is rejected, a recessive mode is preferred. Genet Epidemiol (1991) 1.60
Self-reported dark red bleeding as a marker comparable with occult blood testing in screening for large bowel neoplasms. Br J Surg (1983) 1.59